VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs' commitment to rigorous scientific standards, regulatory excellence, and transformative health solutions, empowering the company to accelerate AI-driven advancements in musculoskeletal health, pain management, and beyond.
Dr. Gagnier brings highly credentialed academic and clinical epidemiology leadership to Fifty1 AI Labs. With a Doctor of Naturopathic Medicine (ND) from the Canadian College of Naturopathic Medicine, an MSc and PhD in Clinical Epidemiology & Biostatistics from the University of Toronto, and a post-doctoral fellowship in Epidemiologic Methods at the University of Michigan, he currently serves as Associate Professor in both Epidemiology & Biostatistics and Surgery at Western University's Schulich School of Medicine & Dentistry. As Field Leader of the Clinical Epidemiology & Research Management master's program, Dr. Gagnier has trained the next generation of health researchers. His formal, advanced training establishes strong scientific legitimacy for Fifty1AI Labs, signaling to investors and partners that the company is dedicated to high-quality, evidence-based health research rather than superficial wellness marketing.
A recognized expert in clinical trial methodology, systematic reviews, meta-analyses, outcome measurement, and reporting standards-particularly for patient-reported outcome measures (PROMs), bias assessment, and measurement scale validation-Dr. Gagnier has focused his research on enhancing the properties of health outcome scales, reducing bias in PROMs, and improving trial reporting consistency. This expertise ensures that Fifty1 AI Labs' data and insights are replicable, transparent, and rigorous, providing a key differentiator in risk mitigation, regulatory acceptance, and credibility with customers and collaborators.
Dr. Gagnier's strong domain experience aligns seamlessly with Fifty1 AI Labs' focus areas, including musculoskeletal conditions, perioperative outcomes (such as pain and function), sports medicine, surgical safety, clinical care outcomes, and peptides. His research program emphasizes multi-centered clinical studies and the application of AI and machine learning to trial design and implementation. Having overseen laboratories, supervised students, fellows, and residents, and published extensively in these fields, Dr. Gagnier positions Fifty1 AI Labs to capitalize on large-market opportunities in pain relief, mobility, injury recovery, and personalized interventions, leveraging computational methods for faster, smarter innovation and competitive advantage.
With a proven track record of securing large-scale funding-over CAD $20 million in research grants-publishing more than 210 peer-reviewed papers, delivering over 300 lectures and workshops at international scientific meetings, and holding leadership roles in scientific governance, Dr. Gagnier is Editor-in-Chief and editorial board member for several journals. He is also a member of prestigious groups like the CONSORT Group, Cochrane Collaboration (Musculoskeletal, Back Review, and Bias Methods Groups), and past Chair of the Strategies in Clinical Research Section of the Orthopaedic Research Society. This demonstrates his ability to attract resources, build influence, and reduce execution risk, making Fifty1 AI Labs more attractive for partnerships and investment while ensuring its scientific output is globally respected.
Dr. Gagnier's decades of industry and advisory experience further strengthen his role, including serving as Senior Science Officer at Jamieson Laboratories Ltd., Chief Scientific Officer at Second Life Global, and scientific consultant to global pharma leaders like Sanofi, Johnson & Johnson, Prollenium Medical Technologies, and London Pharmaceutical Sciences Inc. His background in natural health products, herbal medicine research, evidence-based formulation, regulatory submissions (e.g., for CBD and related products), quality control (GMP), and product development addresses investor concerns around regulatory scrutiny and market viability. This real-world expertise ensures Fifty1 AI Labs' innovations are compliant, commercially scalable, and grounded in safety and efficacy.
Committed to innovation in personalized wellness, Dr. Gagnier explores heterogeneity of treatment effects (how individuals respond differently to interventions), reproducibility, transparency, and outcome precision. His work integrates AI/ML for nuanced, precise evidence generation, improving measurement tool validity, reliability, and responsiveness. This approach enables Fifty1 AI Labs to deliver scalable yet personalized solutions that withstand scrutiny, support ethical standards, and command premium market positioning through stronger trust from partners and purchasers.
"We are thrilled to welcome Dr. Joel Gagnier to Fifty1 AI Labs as our Chief Science Officer," said Paul Arora, CEO of Fifty1 AI Labs Inc. "Joel's unparalleled blend of academic rigor, industry acumen, and AI expertise will propel our mission to revolutionize wellness through data-driven, evidence-based innovations. His leadership will not only elevate our research capabilities but also inspire confidence among investors, regulators, and customers as we pioneer the future of personalized health."
"I am excited to join Fifty1 AI Labs at this pivotal moment in AI-enabled health research," said Dr. Joel Gagnier. "By combining cutting-edge clinical epidemiology with machine learning, we can unlock precise, reproducible insights into wellness interventions, from peptides to pain management. I look forward to driving scientific excellence that translates into real-world impact for individuals seeking optimized health outcomes."
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is revolutionizing drug discovery by leveraging AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
Contact:
Investor Relations
Fifty1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing, the scalability of transportability frameworks, and the ability of Fifty1 AI Labs' platform to transform oncology and global health outcomes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of partnerships and projects, the efficacy and safety of repurposed treatments, regulatory approvals, and the company's ability to successfully develop and commercialize its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, please refer to Fifty1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
